When someone is diagnosed with oropharyngeal cancer — a form of head and neck cancer — the first question is often about treatment. The second is just as important: What will treatment mean for my quality of life?
A new major Phase III study published in The Lancet provides encouraging answers to both questions. For the first time, researchers directly compare proton therapy with traditional radiation in patients with oropharyngeal cancer, giving a clear look at how these treatments stack up.
For years, evidence supporting proton therapy in head and neck cancers has come primarily from observational studies and retrospective analyses. While promising, those studies left room for debate.
This new trial changes that.
By randomly assigning patients to receive either proton or photon radiation therapy, researchers were able to directly compare outcomes — offering the strongest clinical evidence to date.
“Until now, evidence favoring proton therapy in these cancers came mostly from single-arm or observational cohorts,” said Andrew K. Lee, M.D., MPH, medical director for Texas Center for Proton Therapy, a part of Texas Oncology. “This trial provides prospective, randomized data directly comparing treatment approaches and strengthens the clinical evidence supporting proton therapy.”
The results suggest that, for appropriately selected patients, proton therapy may offer important benefits:
Five-year survival was 90.9% among patients treated with proton therapy, compared to 81% for those receiving conventional radiation — a statistically significant difference.
Importantly, proton therapy maintained non-inferior disease control, meaning it was very effective at controlling the cancer.
Patients receiving proton therapy experienced significantly lower rates of several serious treatment-related toxicities commonly associated with head and neck radiation, including:
The study also found that patients treated with proton therapy were 33% less likely to need a feeding tube at 60 days, a 13% absolute difference, which suggests better swallowing and improved short-term recovery.
Proton therapy’s precise approach to treatment allows radiation to better match the shape of the tumor while reducing exposure to nearby healthy tissues. This difference in how the dose is delivered appears to lead to meaningful clinical benefits — not just in survival, but in daily quality of life.
“These results suggest proton therapy as an important treatment option for many oropharyngeal cancer patients, combining strong disease control with meaningful quality-of-life advantages,” said Jared Sturgeon, M.D., Ph.D., Texas Center for Proton Therapy physician. “Reducing treatment-related complications helps patients recover more smoothly and supports better long-term functional outcomes.”
As cancer care continues to advance, studies like this help guide treatment decisions and provide patients with evidence-based options that prioritize both survival and life after treatment.
